Clinical applications of (pharmaco)metabolomics
The predication of the effect (efficiency and toxicity) of a drug in a patient is very important in (i) clinical decision support and (ii) the development of novel drug treatments. We apply our technology and methods to find biomarkers for key disease pathways and toxicity in clinical studies and in in-vitro (organ-on-a-chip) and animal models. For example, we try to understand why 30% of diabetic patients develop kidney disease, and why not all patients benefit from pharmacological treatment to prevent kidney disease. This can help to predict the proper treatment of patients (who needs what treatment), and to develop novel pharmacological interventions taking interindividual differences within patients into account.
- Thomas Hankemeier
In our research and collaborations, we work mainly on (cardio)vascular, metabolic and CNS diseases, infectious diseases, cancer and pharmacology in order to develop generic concepts that will help progress personalized health strategies. We aim to develop translational models of systems pathophysiology and pharmacology, based on our core expertise’s ranging from in-vitro models, to translational metabolomics and translational pharmacology to clinical pharmacology. Our translational approach will allow us to study and model the variation of a disease and pharmacology better between sub-groups of patients, right down to the individual level.